



RESEARCH ARTICLE

Antihypertensive and vasorelaxant effects of *Salvia tingitana* in rats

Amine Azzane*, Adil Qabouche, Ismail Bouadid & Mohamed Eddouks*

Ethnopharmacology and Pharmacognosy, Faculty of Sciences and Techniques, Errachidia, Moulay Ismail University of Meknes, BP 509, Boutalamine, Errachidia 52000, Morocco

*Correspondence email - azzane1amine@gmail.com; mohamededdouks2017@gmail.com

Received: 03 December 2024; Accepted: 04 March 2025; Available online: Version 1.0: 29 April 2025; Version 2.0: 26 July 2025

Cite this article: Azzane A, Qabouche A, Bouadid I, Eddouks M. Antihypertensive and vasorelaxant effects of *Salvia tingitana* in rats. Plant Science Today. 2025; 12(3): 1-8. <https://doi.org/10.14719/pst.6510>

Abstract

Salvia tingitana (*S. tingitana*) is a medicinal and aromatic plant that belongs to the Lamiaceae family with several medicinal properties. Secondary metabolites, including flavonoids, polyphenols and tannins, were identified through phytochemical analysis of the aerial parts of *S. tingitana*. In addition, pharmacological investigation revealed this plants' antihyperglycemic and antihyperlipidemic activities. This study aimed to investigate the antihypertensive and vasorelaxant activities of the aqueous extract of *S. tingitana* (AEST) in normal and L-NAME-induced hypertensive rats by assessing its effects on heart rate (HR), systolic blood pressure (SBP), mean blood pressure (MBP) and diastolic blood pressure (DBP). The study further investigated the vasorelaxant effect of AEST on isolated rat thoracic aorta and elucidated the underlying mechanisms. As a result, AEST significantly lowered SBP after single and repeated oral administration in normal rats without affecting MBP, DBP and heart rate. Interestingly, after repeated oral AEST administration, arterial blood pressure parameters (SABP, DBP and MBP) significantly decreased in hypertensive rats. The vasorelaxation effect induced by AEST in aortic rings was mediated through numerous pathways involving calcium channels, nitric oxide synthase, muscarinic receptors and inward-rectifying potassium channels. In contrast, the pretreatment with methylene blue, glibenclamide, indomethacin and propranolol did not significantly alter AEST-induced vasorelaxation. The study showed that AEST exhibits a significant antihypertensive effect in L-NAME-rats and exhibits vasorelaxant properties in rat aortic rings via mechanisms involving calcium channels, nitric oxide synthase, muscarinic receptors and inward-rectifying K⁺ Channels. Interestingly, many further studies on the structure-activity relationship of *S. tingitana* are needed to explain the mechanisms of action that have been revealed.

Keywords: antihypertensive effect; hypertension; *Salvia tingitana*; vasorelaxant effect

Introduction

Globally, cardiovascular illnesses are the major reasons of death. Hypertension (high blood pressure) is a major cause of cardiovascular ailments (1). Interestingly, hypertension is classified as a 'silent killer' and is primarily identified through screening programs and blood pressure monitoring (2). Hypertension is diagnosed when a patients' systolic and diastolic blood pressures exceed 140 mm Hg and 90 mm Hg, respectively (3). Concerning the treatment, medicinal plants have a long history in the treatment and control of this ailment; especially the use of modern medication available for treating hypertension can present various side effects (4).

Lamiaceae are a group of herbal remedies traditionally used for centuries in conventional medicine to manage cardiovascular illnesses. In addition to essential oils, these herbs make extracts and isolates such as polyphenols, phenolic compounds, terpenes, iridoids and terpenes (5). Correspondingly, genus *Salvia* is one of the essential genera of the Lamiaceae family, which has important effects in controlling hypertension. Indeed, *salvia aucheri* revealed a

potent antihypertensive and vasorelaxant activity mediated through nitric oxide and NO-cyclic guanosine monophosphate pathways (6). Other pharmacological studies have revealed that genus *Salvia* reduces blood pressure through inhibiting oxidative stress, inflammation and fibrosis (7).

Originally from the Middle East and North Africa, *S. tingitana* is a medicinal and aromatic plant of the Lamiaceae family (8). Phytochemical analysis of *S. tingitana* aerial parts revealed the presence of enormous secondary metabolites such as a labdanes, nor-sesterterpenoid, sesterterpenoids, sesquiterpenoid, flavonoids, diterpenoid, polyphenols and tannins (9, 10). Importantly, we have previously revealed that aqueous extract of this plant exhibits a remarkable diminution effect of plasma glucose values after treating diabetic and normal rats. Furthermore, the administration of this aqueous extract revealed a potent amelioration in lipoprotein and lipid profiles (10). In addition to antidiabetic and antidyslipidemic abilities, *S. tingitana* aqueous extract (AEST) is a potent antimicrobial agent against important Gram-positive human pathogens (11). Although so far, until now no pharmacological work was

carried out to reveal the antihypertensive and vasorelaxant effect of *S. tingitana*. Hence, the main goal of this work was to display the effect of AEST in L-NAME (L-NG-Nitro arginine methyl ester) model hypertensive and normal rats, as well as to discover the underlying mechanisms involved in vasodilation through *ex vivo* vascular reactivity experiments using isolated rat aortic rings.

Materials and Methods

Plant material

In March 2021, *S. tingitana* was purchased fresh from a local market in Morocco's Tafilalet region (semi-arid region). A voucher specimen of the plant was deposited in Errachidias' Faculty of Sciences and Techniques herbarium after being taxonomically identified and authenticated (ST 25/35).

Preparation of the aqueous

Based on the conventional Moroccan approach, the decoction was used to prepare the *S. tingitana* aqueous extract (12). 4 g of *S. tingitana* powder were boiled in 400 mL of distilled water for 10 min and then cooled for 20 min. A Millipore filter (Millipore 0.2 mm, St Quentin en Yvelines, France) was then used to remove particulate matter from the aqueous extract. After the filtration of extract, the last was lyophilized in a freeze dryer (Labcono, Boyer, Casablanca, Morocco) (13). In this work, a preliminary dose screening was carried out, a series of doses (10, 20, 40, 60 and 80 mg/kg) were tested to determine the appropriate dose that will be used. Each dose was administered to three rats. The dose of 80 mg/kg was identified as the minimum dose which in this case would induce significant antihypertensive activity.

Experimental animals

In Morocco, healthy albino male rats were obtained from the Experimental Center of Missouri. The weight of rats ranges between 140 and 240 g (6 to 8 weeks old). Rats were housed in individual polyethylene cages under conventional experimental conditions and provided with *ad libitum* consumption of a standard pellet diet (14). All of the tests were carried out following local ethics guidelines (FSTE/2015) after a three-week acclimation period to alleviate shipping stress.

Antihypertensive activity

At a dose of 60 mg/kg L-NAME body weight (b.w) is used in this study to induce hypertension in male rats by repeated oral administration (during 21 days). Distilled water was administered in this study concerning control group. L-NAME hypertensive and normal rats were randomly divided into three groups, each containing six rats. The first group received the aqueous extract of aerial parts of AEST (80 mg/kg b.w). The second group received lasilix (furosemide; 20 mg/kg b.w) and the last received distilled water (control group). Concerning single oral administration (6 hr), AELP, lasilix and distilled water were administered orally and the heart rate (HR) and blood pressure parameters (DBP (diastolic blood pressure), SBP (systolic blood pressure) and MBP (mean blood pressure)) were followed after 6 hr of treatment. Identically, AELP, lasilix and distilled water were administered orally every day for 1 week and SBP, DBP, MBP and HR were detected. The measurements were taken

throughout a period of repeated oral administration. To prevent immobilization stress induction, the rats were anaesthetized *via* the respiratory route with ether (50 %) for approximately 2 min and blood pressure was estimated as previously described (15).

Evaluation of vascular dilatation

The vascular relaxation measurement and mechanism evaluation were performed as described (16).

Statistical analysis

Following the blinded collection and data analysis, the statistical significance of data was tested between three groups using two-way ANOVA with Prism version 8 (Graph Pad Software Inc, San Diego, CA, USA) followed by the Bonferroni multiple comparisons tests. The probability of $p < 0.05$ established the significance of differences. Data were presented as mean $\pm$ SEM.

Results

Body weight changes after the administration of AEST

The study revealed that AEST administration at a dose of 80 mg/kg had no observable effect on b.w in any of the experimental groups during the subchronic study. (Data not shown).

Acute oral administration

Oral L-NAME administration revealed an augmentation effect of all the blood pressure parameters, including SBP, DBP and MBP, compared to baseline value. The impact of AEST on heart rate and blood pressure parameters in hypertensive and normal rats are presented in Table 1. In L-NAME rats, AEST induced a considerable reduction effect of SBP ($p < 0.001$), DBP ($p < 0.05$) and MBP ($p < 0.001$) after 6 hr of administration. In the furosemide-treated rats, a considerable lowering effect of SBP ($p < 0.05$), DBP ($p < 0.05$) and MBP ($p < 0.01$) was observed. However, the heart rate remained unchanged after 6 hr of oral furosemide administration compared to the baseline value. Nevertheless, there is no significant variation in heart rate after the same treatment period by AEST and standard medicament. Similarly, the control group also showed no changes in heart rate or arterial blood pressure parameters.

Repeated oral administration

Table 2 summarizes the effects of AEST on heart rate and SBP, MBP and DBP in normal and hypertensive rats after a seven-day treatment period. In this test, AEST (80 mg/kg) was administered orally to anaesthetized hypertensive rats over seven days.

In hypertensive rats, the finding showed that AEST produced a remarkable diminution of SBP and DBP at the fourth ($p < 0.05$) and seventh ($p < 0.0001$) days of administration. AEST provoked a significant lowering effect of MBP on the seventh ($p < 0.0001$) day of oral administration. Still, no variation was recorded in the rats treated with the same extract concerning heart rate. The subchronic experiment demonstrated a substantial reduction of DBP and SBP in L-NAME rats treated with the standard drug (furosemide). This reduction was noted at the second, fourth

Table 1. Effect of single oral administration (acute test) of AEST (80 mg/kg) on systolic, mean, diastolic arterial blood pressure (mm Hg) and heart rate (bpm) in normotensive and L-NAME hypertensive animals

Groups		Systolic blood pressure (mmHg)		
		Control	AEST	Furosemide
Normal	T ₀	132±6	122.75±3.4	120±7
	T ₆	138±8	95±7.57*	111±7
L-NAME	T ₀	180±5	175.5±5.91	169±7
	T ₆	175±7	135.25±5.80***	142±6*
		Mean blood pressure (mmHg)		
		Control	AEST80mg/kg	Furosemide
Normal	T ₀	115±7	92±6.3	108±6
	T ₆	113±6	79.8±6.09	97±2
L-NAME	T ₀	156±6	153.87±5.37	150±3
	T ₆	157±6	121.5±4.36***	125±6**
		Diastolic blood pressure (mmHg)		
		Control	AEST80mg/kg	Furosemide
Normal	T ₀	106±5	76.6±7.96	103±5
	T ₆	101±6	72.25±5.78	91±4
L-NAME	T ₀	144±7	142.9±5.36	152±5
	T ₆	148±10	114.65±3.81*	129±4*
		Heart rate (bpm)		
		Control	AEST	Furosemide
Normal	T ₀	320±10	332±3	349±19
	T ₆	306±8	322±5	321±9
L-NAME	T ₀	312±15	334±1	348±22
	T ₆	318±12	349±8	311±17

Data are expressed as Mean±SE, n=6. *p<0.05, **p<0.01, ***p<0.001 when compared to the baseline value (T₀). T: time (hour)

Table 2. Effect of repeated oral administration (chronic test) of AEPG (120 mg/kg) on systolic, mean, diastolic arterial blood pressure (mm Hg) and heart rate (bpm) in normotensive and L-NAME hypertensive rats

		Systolic blood pressure (mm Hg)		
		Control	AEST	Furosemide
Normal	D ₀	132 ± 6	122.75±3.4	120 ± 7
	D ₂	136 ± 5	128.25±1.1	115 ± 5
	D ₄	140 ± 3	97.5±4.75	108 ± 3
	D ₇	135 ± 6	92.25± 6.22 *	99 ± 4**
	D ₀	180 ± 5	175.5±5.91	169 ± 6
L-NAME	D ₂	176 ± 5	154.25±10.29	122 ± 2****
	D ₄	173 ± 9	149.75±4.75*	120 ± 4****
	D ₇	172 ± 6	130±3.97****	109 ± 3****
		Mean blood pressure (mm Hg)		
		Control	AEST	Furosemide
Normal	D ₀	115 ± 7	92±6.37	108 ± 6
	D ₂	112 ± 5	113.25±2.32	107 ± 5
	D ₄	117 ± 6	81.25±6.92	101 ± 3
	D ₇	112 ± 4	78.25±7.25	96 ± 2
	D ₀	156 ± 6	153.87±5.37	150 ± 3
L-NAME	D ₂	149 ± 6	141±9.74	148 ± 5
	D ₄	148 ± 9	130±5.61	103 ± 5****
	D ₇	147 ± 6	111±5.01****	95 ± 4****
		Diastolic blood pressure (mm Hg)		
		Control	AEST	Furosemide
Normal	D ₀	106 ± 5	76.62±7.96	103 ± 5
	D ₂	101 ± 5	105.75±2.93	98 ± 5
	D ₄	106 ± 3	73±3.71	97 ± 6
	D ₇	102 ± 8	99.75±1.65	95 ± 4
	D ₀	144 ± 7	142.9±5.36	152 ± 5
L-NAME	D ₂	135 ± 7	134±9.57	103 ± 4****
	D ₄	135 ± 6	120±6.61*	100 ± 4****
	D ₇	136 ± 6	94±5.63****	98 ± 3****
		Heart rate (bpm)		
		Control	AEST 80 mg/kg	Furosemide
Normal	D ₀	320 ± 10	312±5	349 ± 19
	D ₂	320 ± 14	299±6	341 ± 16
	D ₄	312 ± 16	305±8	341 ± 17
	D ₇	319 ± 8	302±4	305 ± 8*
	D ₀	312 ± 15	315±5	348 ± 22
L-NAME	D ₂	310 ± 15	317±6	343 ± 13
	D ₄	307 ± 13	324±4	315.00 ± 11
	D ₇	318 ± 18	298±7	311.00 ± 10

Data are expressed as mean ±SEM, n= 6. *p<0.05, **p<0.01, ***p<0.001 ****p<0.0001 when compared to the baseline value (T₀). D: day

and seventh ($p < 0.0001$) days of treatment. Identically, during the subchronic treatment essay, MBP significantly decreased in hypertensive rats treated with furosemide on the fourth and seventh days ($p < 0.0001$). In contrast, the heart rate remained unchanged during the treatment period by furosemide. No notable modifications were noticed in blood pressure measurements or heart rate in the non-treated group over the administered duration.

In normal rats, the results demonstrated that the AEST caused a remarkable decline effect of SBP at the seventh ($p < 0.05$) day of treatment. In contrast, no observable changes impact heart rate, DBP and MBP after seven days of treatment. Furosemide-treated rats showed a substantial lowering effect of SBP and heart rate on the seventh day from the treatment in the regular group ($p < 0.01$) and ($p < 0.05$), respectively.

Vasorelaxant effect and mechanisms implicated

Vasorelaxant effect of AEST

AEST was tested using isolated aortic rings pre-contracted with KCL or norepinephrine (EP; 10^{-5}) to determine its effect on vascular relaxation. The relaxation effects of five different concentrations were investigated in a series of experiments (0.0625, 0.125, 0.187, 0.3125, 0.5 mg/mL) in a dose-dependent method. It has been shown that AEST induced a vasorelaxation effect in aortic rings that were pre-contracted by KCL or EP (Fig. 1). Indeed, AEST demonstrated a significant concentration-dependent vasodilatation effect on aorta pre-contracted with EP (Fig. 1A), with considerable dilation observed from the initial dose of 0.0625 mg/mL ($p < 0.01$) to the other doses (0.125, 0.187, 0.3125, 0.5 mg/mL, $p < 0.0001$). The vasorelaxation effect induced by AEST was achieved at an EC_{50} value of 0.133 ± 0.04 mg/mL and a R_{max} value of 128.5 ± 26.04 %. In addition, AEST did not change significantly the contraction produced by KCL (Fig. 1B) concerning the first two doses (0.125, 0.187 mg/mL). The relaxant effect in these aortic rings (pre-contracted by KCL) was observed after the incubation of aortic rings by the third (0.3125 mg/mL, $p < 0.01$)

and the fourth (0.5 mg/mL, $p < 0.0001$). Notably, the results demonstrate that AEST induced an antihypertensive effect by the vasodilation of vascular smooth muscle. To define the mechanism responsible for this vasorelaxant activity caused by the incubation of AEST, several drugs were employed in this work after a pre-contract with EP.

Responses of the aorta to AEST without and with glibenclamide or propranolol

To investigate the integration of β -adrenergic receptors or potassium channels in AEST-induced relaxation, aortic rings were pre-incubated with propranolol (a β -adrenergic receptor blocker) or glibenclamide (a potassium channel inhibitor) before being contracted with EP (EP). The preincubation with neither glibenclamide (Fig. 2A) nor propranolol (Fig. 2B) significantly altered the vasoactivity effects of AEST in comparison with the control.

Responses of the aorta to AEST without and with indomethacin or L-NAME

The aortic rings with intact endothelium were pre-treated with NO synthase inhibitor (L-NAME) or prostaglandin synthesis inhibitor (indomethacin). The analysis results are depicted in Fig. 3. Correspondingly, the results show that L-NAME and indomethacin treatment didn't alter the vasorelaxation caused by AEST compared to the baseline value.

Analysis of aortic responses to AEST with or without nifedipine or methylene blue

To evaluate whether NO-cyclic guanosine monophosphate (cGMP) and Ca^{2+} channels are involved in the AEST vasodilatation activity. Methylene blue or nifedipine are pre-treated of aortic rings. The data were analyzed and are graphically represented in Fig. 4. The findings confirm that incubation of methylene blue altered the vasocontractility ability produced by AEST from the second to the fourth dose ($p < 0.01$; Fig. 4A). In the same vein, the preincubation of nifedipine changed the vasocontractility effect produced by the same extract at the same doses ($p < 0.05$; Fig. 4B).




Fig. 1. Effect of AEST on EP and KCL-induced contraction in thoracic aortic rings. Cumulative dose-dependent curves for AEST-induced relaxation and distilled water in rat aortic rings. $n = 6$; (A). pre-contraction with norepinephrine ($10 \mu\text{M}$); (B). pre-contraction KCL (80 mM). ** $p < 0.01$, **** $p < 0.0001$.




Fig. 2. Effect of glibenclamide and propranolol incubation on AEST-induced vasorelaxation. Aortic rings were pre-incubated with cumulative doses of AEST in the absence or presence of the following drugs: (A) Glibenclamide; (B) Propranolol. Data represent mean $\pm$ SEM.




Fig. 3. Effect of different drugs incubation on AEST-induced relaxation. Aortic rings were pre-incubated with cumulative doses of AEST in the absence or presence of the following drugs: (A) L-NAME; (B) Indomethacin.. Data represent mean $\pm$ SEM.




Fig. 4. Effect of different drugs incubation on AEST-induced relaxation. Aortic rings were pre-incubated with cumulative doses of AEST in the absence or presence of the following drugs: (A) Methylene blue; (B) Nifedipine. * $p < 0.05$, ** $p < 0.01$. Data represent mean $\pm$ SEM.

Analysis of aortic responses to AEST with or without BaCl₂ or atropine

To understand if the pathways of BaCl₂ or Atropine are implicated in the vasorelaxant action involved in AEST on endothelium-intact rat aortic rings, BaCl₂ or Atropine preincubation was used in a series of experiments. The results are shown in Fig. 5. The presence of BaCl₂ significantly reduced AEST-induced dilatation after the incubation of aortic rings by the last four doses (0.125, 0.187, 0.3125, 0.5 mg/mL, $p < 0.01$) in comparison to the control (Fig. 5A). Identically, the incubation of atropine before EP-evoked contraction significantly attenuated AEST-induced relaxation after the incubation of aortic rings by the third, fourth and higher doses ($p < 0.01$; Fig. 5A) when the responses were compared to that of aortic rings pre-contracted exclusively with EP.

Discussion

One-week studies were conducted on normal and L-NAME-rats to evaluate the antihypertensive effect of *S. tingitana* extract. In addition, the vasorelaxant ability has been discovered to determine the possible mechanisms involved in the antihypertensive response using isolated rat aorta. An experimental hypertensive state was induced in Wistar rats by administering L-NAME over seven days. In the present study, AEST decreased the parameters of arterial blood pressure without affecting the heart rate in hypertensive rats. AEST significantly lowered SBP after 6 hr of administration in normal rats without affecting MBP, DBP and heart rate. Interestingly, following repeated oral administration of AEST, arterial blood pressure parameters (SABP, DBP and MBP) significantly decreased in hypertensive rats; however, heart rate did not change. Repeated oral AEST treatment over seven days had no effects on heart rate or the parameters of arterial blood pressure in normal rats. Secondary metabolites are beneficial in the treatment of hypertension in several studies. In L-NAME-induced hypertensive rats, these secondary metabolites may act individually or synergistically to lower blood pressure (17). In the same vein, several works revealed the existence of numerous phytochemical compounds like tannins, alkaloids, flavonoids and polyphenols in *S. tingitana* (9, 10). Notably, the consumption of foods with high

percentages of polyphenolic is linked with diminution incidence of cardiovascular illness; this effect is probably due to the capacity of polyphenols to prevent leukocyte adhesion and platelet aggregation, to promote relaxation of vascular smooth muscle and to protect LDL (low-density lipoprotein) from oxidation (18, 19). In addition, polyphenols may act on the metabolism of cells such as nitric oxide (NO), thrombus development and vascular tone (20-22).

It is possible to lower arterial pressure by reducing cardiac output or systemic vascular resistance (23). AEST was shown to be a potent vasorelaxant in aortic rings pre-contracted with EP, as evidenced by the experimental results; this effect was also attenuated after the precontraction of aortic rings by KCL. Importantly, it induced vasoconstriction by stimulation of voltage-operated Ca²⁺ channels (24), suggesting the intervention of Ca²⁺ channels in the vasorelaxant effect observed after the incubation of AEST.

The observed vasodilatory capacity of AEST likely plays a significant role in its antihypertensive effects. An *ex vivo* study was undertaken to elucidate the potential mechanisms associated with this vasodilation activity. Indeed, a total of eight reference drugs, were pre-incubated in rat aortic rings, including indomethacin (a prostaglandin synthesis inhibitor), glibenclamide (an ATP-sensitive K⁺ channel blocker), methylene blue (a cyclic guanosine monophosphate blocker), atropine (muscarinic receptors blocker), L-NAME (a nonselective nitric oxide synthase inhibitor), propranolol (a beta-blocker), nifedipine (a calcium channel blocker) and BaCl₂ (inward-rectifying K⁺ channels (KIR) inhibitor). The findings revealed that preincubation of aortic rings with propranolol, glibenclamide, methylene blue and indomethacin did not alter the vasorelaxation effect produced by the AEST. In contrast, nifedipine, L-NAME, atropine and BaCl₂ have reduced the vasorelaxant ability of AEST. Medicinal plant extracts have previously reported calcium channel inhibition (25). In general, calcium entry into the cell cytosol can occur through two primary mechanisms: the influx from the extracellular space via voltage-gated calcium channels. The second is calcium release from the intracellular sarcoplasmic reticulum stored in the cytosol (26). Nifedipine, a member of the dihydropyridine group of a selective antagonists of calcium channels, is indicated for




Fig. 5. Effect of different drugs incubation on AEST-induced relaxation. Aortic rings were pre- incubated by cumulative doses of AEST leaves in the absence or presence of the following drugs: (A) BaCl₂; (B) Atropine. ** $p < 0.01$. Data represent mean $\pm$ SEM.

treating chronic stable angina and vasospastic. As well as, nifedipine is effective in treating essential hypertension (relaxed vascular smooth muscle), acute hypertensive crises and achalasia (27). In the present study, nifedipine has partially inhibited the vasorelaxant activity of AEST, indicating the role of calcium channels in this pharmacological activity.

In endothelium, the continual production of NO keeps the balance between vasoconstriction and vasodilation (28). Indeed, NO plays a crucial role in cardiovascular function, primarily by inducing vasorelaxation and regulating vascular tone (29). Reduced NO production has been implicated in various cardiovascular diseases, including hypertension, coronary vasospasm and increased systemic vascular resistance (30). In contrast, augmentation of NO production causes inflammation and neurodegenerative diseases (31). This finding suggests the critical role of NO in the vasodilatory effect of AEST, as evidenced by the partial inhibition of this effect by L-NAME.

In addition, the results show that the presence of atropine attenuated significantly the vasorelaxant effect provoked by AEST, so it is hypothesized that the impact of this plant may be mediated partially by the muscarinic receptor. By blocking muscarinic receptors, atropine can inhibit the inhibitory effects of acetylcholine (30). In addition, it has been suggested that at the dose of 10-8 M (lower concentrations), atropine blocks muscarinic receptors, leading to inducing contraction effects. In contrast, at a dose of 10-3 M (large dose), atropine increased intracellular calcium sequestration, leading to the induced relaxation effect (32). The activity of potassium ion (K⁺) channels directly impacts vascular smooth muscle membrane potential, which in turn determines vascular tone. Inward-rectifying potassium (K⁺) channels in vascular smooth muscle exhibit distinct characteristics compared to other types of K⁺ channels, including voltage-dependent K⁺ channels (KV channels), ATP-sensitive K⁺ channels (KATP channels) and Ca²⁺-activated K⁺ channels. In addition, inward-rectifying K⁺ channels mediate K⁺-induced relaxation in rat arteries and contribute to basal vasodilation in human forearms (28, 33-37). BaCl₂, in the present study, can partially inhibit the vasorelaxant effect of AEST, indicating the implication of inward-rectifying K⁺ channels in this vasorelaxant effect.

Conclusion

The current study demonstrates clearly that AEST provokes a pronounced antihypertensive activity in L-NAME rats. Interestingly, the vasodilation effect of AEST appears to be mediated by the activation of nitric oxide synthase, calcium channels, muscarinic receptors and inward-rectifying K⁺ channels. The phytochemicals responsible for this pharmacological property need to be identified in further studies.

Acknowledgements

We thank the Hassan II Academy of Science and Technology and the National Center for Scientific and Technical Research (CNRST) for funding this work.

Authors' contributions

AA conducted the investigation, interpreted the data, and drafted the manuscript. AQ performed the analysis, investigation and interpretation of the data. IB assisted in the investigation and contributed to the manuscript's drafting. ME conceptualized the study, critically revised the manuscript and supervised the research. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest: Authors do not have any conflict of interests to declare.

Ethical issues: No humans were involved in the study. All animal procedures were performed per the local ethical committee guidelines, Faculty of Sciences & Techniques Errachidia, Morocco, N° FSTE/2015.

References

- Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization; 2011. p. 155.
- Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment and control of hypertension in rural and urban communities in high-, middle- and low-income countries. *JAMA*. 2013;310(9):959–68. <https://doi.org/10.1001/jama.2013.184182>
- Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension*. 2020;75(6):1334–57. <https://doi.org/10.1161/hypertensionaha.120.15026>
- Eddouks M, Maghrani M, Lemhadri A, Ouahidi ML, Jouad H. Ethnopharmacological survey of medicinal plants used for the treatment of diabetes mellitus, hypertension and cardiac diseases in the south-east region of Morocco (Tafilalet). 2002;82(2-3):97–103. [https://doi.org/10.1016/S03788741\(02\)00164-2](https://doi.org/10.1016/S03788741(02)00164-2)
- Patrignani F, Prasad S, Novakovic M, Marin PD, Bukvicki D. 612 Lamiaceae in the treatment of cardiovascular diseases. *Fron Biosci*. 2021;26(4):612–43. <https://doi.org/10.2741/4909>
- Azzane A, Amssayef A, Eddouks M. *Salvia aucheri* Exhibits Antihypertensive Activity in Hypertensive Rats. *Cardiovasc Hematol Agents Med Chem*. 2023;21(3):167–76. <https://doi.org/10.2174/1871525721666221221163432>
- Wu R, Zhou Y, Xu H, Zhao W, Zhou L, Zhao Y, et al. Aqueous extract of *Salvia miltiorrhiza* Bunge reduces blood pressure through inhibiting oxidative stress, inflammation and fibrosis of adventitia in primary hypertension. *Front Pharmacol*. 2023;14:1093669. <https://doi.org/10.3389/fphar.2023.1093669>
- Foley MJY, Hedge IC, Möller M. The enigmatic *Salvia tingitana* (Lamiaceae): a case study in history, taxonomy and cytology. *Willdenowia*. 2008;38(1):41. <https://doi.org/10.3372/wi.38.38102>
- Ravera S, Esposito A, Degan P, Caicci F, Manni L, Liguori A, et al. The diterpene Manool extracted from *Salvia tingitana* lowers free radical production in retinal rod outer segments by inhibiting the extramitochondrial F1Fo ATP synthase. *Cell Biochem Funct*. 2021;39(4):528–35. <https://doi.org/10.1002/cbf.3618>
- Azzane A, Eddouks M. Antihyperglycemic, Antihyperlipidemic and Antioxidant Effects of *Salvia tingitana* in Streptozotocin-Induced Diabetic Rats. *Cardiovasc Haematol Dis Drug Targets*. 2022;22(2):118–27. <https://doi.org/10.2174/1871529X22666220806122012>

11. Bisio A, Schito AM, Pedrelli F, et al. Antibacterial and ATP synthesis modulating compounds from *Salvia tingitana*. J Nat Prod. 2020;83(4):1027–42. <https://doi.org/10.1021/acs.jnatprod.9b01024>
12. Azzane A, Farid O, Eddouks M. Antihyperglycemic and Antidyslipidemic Effects of *Artemisia arborescens* Aqueous Extract on Streptozotocin-induced Diabetic Rats. Cardiovasc Hematol Agents Med Chem. 2023;21(2):120–38. <https://doi.org/10.2174/1871525720666220425094135>
13. Azzane A, Amssayef A, Eddouks M. Antihyperglycemic and Antidyslipidemic Effect of *Moricandia Suffruticosa* in Normal and Streptozotocin-induced Diabetic Rats. Cardiovasc Haematol Dis-Drug Targets. 2022;22(1):58–66. <https://doi.org/10.2174/1871529X22666220513124452>
14. Azzane A, Amssayef A, El-Haidani A, Eddouks M. Effect of *Pulicaria mauritanica* on Glucose Metabolism and Glycogen Content in Streptozotocin-Induced Diabetic Rats. Cardiovasc Hematol Agents Med Chem. 2022;20(3):197–211. <https://doi.org/10.2174/1871525720666220510204624>
15. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838–43. <https://doi.org/10.1074/jbc.M200581200>
16. Boua BB, Kouassi KC, Mamyrbékova-Békro J.A, Kouamé B.A, Békro Y. A. Études Chimique et Pharmacologique de Deux Plantes Utilisées Dans le Traitement Traditionnel de L'hypertension Artérielle à Assoumoukro (Côte D'ivoire). Eur J Sci Res. 2013;97(3):448–62.
17. Rawat P, Singh PK, Vipin K. Antihypertensive Medicinal Plants and their Modof Action. J Herbal Med. 2016;6(3):107–18. <https://doi.org/10.1016/j.hermed.2016.06.001>
18. Study Z, Keli SO, Hertog MGL, Feskens EJM, Kromhout D. Dietary Flavonoids, Antioxidant Vitamins and Incidence of Stroke: the Zutphen study. Arch Int Med.1996;156(6):637–42. <https://doi.org/10.1001/archinte.1996.00440060059007>
19. Wu TW, Chu YC, Chang CH, Hsieh YH, Tang MH, Hsu PH, et al. Flavonol-Ruthenium Complexes as Antioxidant and Anticancer Agents. ChemMedChem. 2024;19(24):e202400313. <https://doi.org/10.1002/cmdc.202400313>
20. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327(6122):524–26. <https://doi.org/10.1038/327524a0>
21. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. The Lancet. 1987;330(8567):1057–58. [https://doi.org/10.1016/S0140-6736\(87\)91481-4](https://doi.org/10.1016/S0140-6736(87)91481-4)
22. Tummanapalli SS, Kuppusamy R, Yeo JH, Kumar N, New EJ, Willcox MDP. The role of nitric oxide in ocular surface physiology and pathophysiology. The Ocular Surface. 2021;21:37–51. <https://doi.org/10.1016/j.jtos.2021.04.007>
23. Jackson RE, Bellamy MC. Antihypertensive drugs. BJA education. 2015;15(6):280–85. <https://doi.org/10.1093/bjaceaccp/mku061>
24. Adeneye A. Herbal Pharmacotherapy of Hypertension. Phytother Manag Diabetes Hypertens. In: Eddouks M, editor. Phytotherapy in the Management of Diabetes and Hypertension. London: Bentham Book; 2016.p. 3-71.
25. Tan CS, Loh YC, Ng CH, Ch'ng YS, Asmawi MZ, Ahmad M, et al. Antihypertensive and vasodilatory effects of amended Banxia Baizhu Tianma Tang. Biomed Pharmacother. 2018;97(2):985–94. <https://doi.org/10.1016/j.biopha.2017.11.021>
26. Tan CS, Ch'ng YS, Loh YC, Zaini Asmawi M, Ahmad M, Yam MF. Vasorelaxation effect of *Glycyrrhizae uralensis* through the endothelium-dependent Pathway. J Ethnopharmacol. 2017;199:149–60. <https://doi.org/10.1016/j.jep.2017.02.001>
27. Rahman T, Khan MOF. Ca²⁺ Channel Blockers. In: Medicinal Chemistry for Pharmacy Students. Bentham Science Publishers; 2024;40–69. <https://doi.org/10.2174/97898151797291240301>
28. Sawasaki K, Nakamura M, Kimura N, Kawahito K, Yamazaki M, Fujie H, et al. Endothelial-derived nitric oxide impacts vascular smooth muscle cell phenotypes under high wall shear stress conditions. Biochem Biophys Res Commun; 2024;151005. <https://doi.org/10.1016/j.bbrc.2024.151005>
29. Malmström RE, Weitzberg E. Endothelin and nitric oxide in inflammation: Could there be a need for endothelin blocking anti-inflammatory drugs? J Hypertens. 2004;22(1):27–29. <https://doi.org/10.1097/01.hjh.0000098170.36890>
30. Grisham MB, Miles AM. Effects of aminosalicylates and immunosuppressive agents on nitric oxide-dependent N-nitrosation reactions. Biochem Pharmacol. 1994;47(10):1897–1902. [https://doi.org/10.1016/0006-2952\(94\)90320-4](https://doi.org/10.1016/0006-2952(94)90320-4)
31. Oh SJ. 19 Treatment and Management of Disorders of the Neuromuscular Junction. Neuromuscular Disorders: Treatment and Management. 2021;446. <https://doi.org/10.1016/B978-0-323-71317-7.00019-6>
32. Cao YX, Zheng JP, He JY, Li J, Xu CB, Edvinsson L. Atropine Induces Vasodilatation of Rat Mesenteric Artery *in vitro* Mainly by Inhibiting Receptor-Mediated Ca²⁺-Influx and Ca²⁺-Release. Vol. 28, Arch Pharm Res. 2005;28(6):709–15. <https://doi.org/10.1007/BF02969362>
33. Dawes M, Sieniawska C, Delves T, Dwivedi R, Chowienczyk PJ, Ritter JM. Barium reduces resting blood flow and inhibits potassium-induced vasodilation in the human forearm. Circulation. 2002;105(11):1323–28. <https://doi.org/10.1161/hc1102.105651>
34. Knot HJ, Zimmermann PA, Nelson MT. Extracellular K⁺-induced hyperpolarizations and dilatations of rat coronary and cerebral arteries involve inward rectifier K⁺ channels. J Physiol. 1996;492(2):419–30. <https://doi.org/10.1113/jphysiol.1996.sp021318>
35. Lopatin AN, Makhina EN, Nichols CG. Potassium channel block by cytoplasmic polyamines as the mechanism of intrinsic rectification. Nature. 1994;372(6504):366–69. <https://doi.org/10.1038/372366a0>
36. Park WS, Han J, Earm YE. Physiological role of inward rectifier K⁺ channels in vascular smooth muscle cells. Pflugers Arch. 2008;457(1):137–47. <https://doi.org/10.1007/s00424-008-0512-7>
37. Yabré Z, Boly R, Khattabi C El, Ouédraogo M, Ouédraogo R, Gilchrist A, et al. African Journal of Pharmacy and Pharmacology Role of soluble guanylate cyclase and muscarinic receptors in the relaxant effect of *Waltheria indica* L. (Malvaceae) on tracheal smooth muscle. Afr J Pharm Pharmacol. 2024;18(8):142–55. <https://doi.org/10.5897/AJPP2024.5403>

Additional information

Peer review: Publisher thanks Sectional Editor and the other anonymous reviewers for their contribution to the peer review of this work.

Reprints & permissions information is available at https://horizonpublishing.com/journals/index.php/PST/open_access_policy

Publisher's Note: Horizon e-Publishing Group remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Indexing: Plant Science Today, published by Horizon e-Publishing Group, is covered by Scopus, Web of Science, BIOSIS Previews, Clarivate Analytics, NAAS, UGC Care, etc
See https://horizonpublishing.com/journals/index.php/PST/indexing_abstracting

Copyright: © The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited (<https://creativecommons.org/licenses/by/4.0/>)

Publisher information: Plant Science Today is published by HORIZON e-Publishing Group with support from Empirion Publishers Private Limited, Thiruvananthapuram, India.